Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States[1] and the European Union[2][3] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[4][5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.
Clinical data | |
---|---|
Trade names | Signifor, Signifor LAR |
Other names | SOM230 |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous injection, intramuscular injection |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ECHA InfoCard | 100.211.883 |
Chemical and physical data | |
Formula | C58H66N10O9 |
Molar mass | 1047.227 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.[2][7][8]
Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012[2][9] and by the U.S. Food and Drug Administration (FDA) in December 2012.[1][10]
Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014,[11] and had been approved for this indication by the EMA in September 2014.[2][12]